Clinical Trial Update: Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity [Phase 1, Phase 2]

View source ↗

Summary

An early-phase tolerance and pharmacokinetic study of IBI362 at 15 mg is being conducted in adults with moderate to severe obesity; the study is currently activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• IBI362

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Obesity | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING